KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Non-Current Assets (2016 - 2026)

Pacira BioSciences has reported Non-Current Assets over the past 17 years, most recently at $693.6 million for Q1 2026.

  • For Q1 2026, Non-Current Assets fell 16.1% year-over-year to $693.6 million; the TTM value through Mar 2026 reached $2.9 billion, down 15.64%, while the annual FY2025 figure was $716.9 million, 11.31% down from the prior year.
  • Non-Current Assets for Q1 2026 was $693.6 million at Pacira BioSciences, down from $716.9 million in the prior quarter.
  • Over five years, Non-Current Assets peaked at $1.2 billion in Q1 2022 and troughed at $693.6 million in Q1 2026.
  • A 5-year average of $981.6 million and a median of $1.0 billion in 2024 define the central range for Non-Current Assets.
  • Biggest five-year swings in Non-Current Assets: surged 126.49% in 2022 and later fell 24.05% in 2024.
  • Year by year, Non-Current Assets stood at $1.2 billion in 2022, then decreased by 10.02% to $1.1 billion in 2023, then dropped by 24.05% to $808.4 million in 2024, then decreased by 11.31% to $716.9 million in 2025, then decreased by 3.26% to $693.6 million in 2026.
  • Business Quant data shows Non-Current Assets for PCRX at $693.6 million in Q1 2026, $716.9 million in Q4 2025, and $734.8 million in Q3 2025.